Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ocumension Therapeutics
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics
Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.
Incyte gets $40m up front and can earn up to $351.5m in milestones pegged to a Phase III JAK1 inhibitor and a pair of Phase II candidates. Shionogi obtains Asian rights to an allosteric inhibitor for cognitive disorders from Tetra.